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Abstract
Objectives: A number of basic questions about bone biology have not been
answered, including population differences in bone turnover. In part, this stems
from the lack of validated minimally invasive biomarker techniques to measure
bone formation and resorption in field-based population-level research. The pre-
sent study addresses this gap by validating a fingerprick dried blood spot (fDBS)
assay for tartrate-resistant acid phosphatase 5b (TRACP-5b), a well-defined bio-
marker of bone resorption and osteoclast number.
Methods: We adapted a commercially available enzyme-linked immunosorbent
assay (ELISA) kit from MyBiosource for the quantitative determination of TRACP-
5b levels in serum and plasma for use with DBS. We used a rigorous process of
assay modification and validation, including the use of a matched set of 189 adult
plasma, fDBS, and venous DBS (vDBS) samples; parameters evaluated included
precision, reliability, and analyte stability.
Results: Plasma and DBS TRACP-5b concentrations showed a linear relationship.
There were no systematic differences in TRACP-5b levels in fDBS and vDBS,
indicating no significant differences in TRACP-5b distribution between capillary
and venous blood. Parallelism and spike-and-recovery results indicated that matrix
factors in DBS do not interfere with measurement of TRACP-5b levels from DBS
using the validated kit. Intra- and interassay CVs were 5.0% and 12.1%, respec-
tively. DBS samples should preferably be stored frozen but controlled room tem-
perature storage for up to a month may be acceptable.
Conclusions: This DBS-based ELISA assay adds to the methodological toolkit
available to human biologists and will facilitate research on bone turnover in popu-
lation studies.
1 | INTRODUCTION
Bone, which comprises mineralized connective tissue, is a
highly dynamic organ that is continually undergoing remo-
deling, with bone resorption by osteoclasts and bone formation
by osteoblasts (Sims & Martin, 2014). The balance between
bone formation and resorption changes throughout life in ways
that can be informative about life history events, providing a
window into the lived experience of the individual since bone
turnover is shaped not only by genetics, but also mechanical
forces, dietary factors, and other aspects of lifestyle and envi-
ronment. There is, therefore, broad interest in biological anthro-
pology in uncovering the specific factors that influence bone
turnover throughout the life course.
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A number of basic questions about bone biology have
not yet been answered despite steady progress in the epide-
miology and treatment of osteoporosis (Bartl & Frisch,
2009; Madimenos, Liebert, Cepon-Robins, Snodgrass, &
Sugiyama, 2015; Marcus, Dempster, Cauley, & Feldman,
2013). This lack of insight into the factors that affect bone
metabolism stems from a narrow focus on clinical settings in
the context of wealthy nations, as well as the lack of field-
friendly techniques to measure biomarkers of bone forma-
tion and resorption. The impact of the availability of these
technologies is exemplified by the development of portable
calcaneal ultrasonometers to measure bone mineral density;
use of these ultrasonometers allowed researchers to obtain
high-quality data on bone health in rural, isolated populations,
namely indigenous Shuar and nonindigenous Colono from
Ecuador (Madimenos et al., 2011, 2015) and the Tsimane of
Bolivia (Stieglitz et al., 2015; Stieglitz, Trumble, Kaplan, &
Gurven, 2017).
There are currently no validated minimally invasive tech-
niques for the measurement of biomarkers of bone formation
and resorption that can be used in samples collected in field
settings (ie, outside of a clinical laboratory environment).
Although saliva and urine samples have been used to access
certain biomarkers (most notably cortisol and testosterone,
where multiple daily samples are required to document diur-
nal fluctuations), blood is the biological substance of choice
or necessity for many analytes. In particular, capillary whole
blood from a finger prick collected onto filter paper (dried
blood spots [DBS]) has opened a realm of possibilities, and
the last decade has seen the adoption of this method in biolog-
ical anthropology, epidemiology, psychology, and a variety of
other disciplines (Demirev, 2013; Li & Lee, 2014; McDade,
Williams, & Snodgrass, 2007; Mei, Alexander, Adam, &
Hannon, 2001). Advantages of using DBS include simplicity
of collection, ease of transport, generally good analyte stabil-
ity, decreased biohazard risk, and low cost (Freeman et al.,
2018; McDade et al., 2007).
Tartrate-resistant acid phosphatase 5b (TRACP-5b) is a
well-defined biomarker of bone resorption and osteoclast
number encoded by a single gene in humans. TRACP-5 is
expressed in both myeloid lineage cells (eg, macrophages)
and in osteoclasts, but has different secondary modifications
in the two cell types. TRACP-5 produced in myeloid cells is
modified with sialic acid and contains high-mannose-type
sugar chains (TRACP-5a), while TRACP-5 produced by
osteoclasts is not modified with sialic acid and has multi-
antennary complex-type sugar chains (TRACP-5b; Kawaguchi
et al., 2008; Ohashi et al., 2006, 2007). In addition, these two
enzymes have different pH optima of 5.2 and 5.8, respectively.
These biochemical differences are also reflected in the dif-
ferences in phosphatase activity of the two enzymes, with
TRACP-5b displaying a higher specific activity than TRACP-
5a (Janckila, Takahashi, Sun, & Yam, 2001), although the
biological functions of tartrate-resistant acid phosphatases are
still unknown (Janckila & Yam, 2009). Circulating levels
of TRACP-5b correlate with the number of osteoclasts
(Janckila & Yam, 2009) and TRACP-5b is therefore widely
used as a bone metabolic marker of osteoclast-mediated bone
resorption (Chu, Chao, Lin, Janckila, & Yam, 2003; Halleen
et al., 2001, 2002; Hannon et al., 2004; Nenonen et al., 2005).
In the present study, our goal was to validate a commer-
cially available ELISA kit (MyBiosource, MBS704711) for
assessment of TRACP-5b levels in DBS as a proxy for oste-
oclast activity. This research opens the door to investigating
population differences in bone acquisition, turnover, and the
effects of factors such as senescence, nutrition, disease, exer-
cise, pregnancy, and lactation on bone mass.
2 | METHODS
The present study was performed in the Global Health Bio-
marker Laboratory at the University of Oregon and used a
rigorous and systematic process of evaluation, modification,
and validation. All data are available upon request to the first
author.
2.1 | ELISA kit
We validated the Human Tartrate-Resistant Acid Phosphatase
5b ELISA kit (MyBiosource, MBS704711), a quantitative
colorimetric sandwich ELISA developed to assay TRACP-5b
levels in serum, plasma, and tissue homogenates. The mea-
surement range of the kit as reported by the manufacturer is
0.312 IU/L to 20 IU/L, with a reported lower limit of detec-
tion (LOD) for TRACP-5b of 0.078 IU/L. Reported TRACP-
5b levels in the serum of normal, evidently healthy adults of
both sexes range from 1.89 ± 0.81 IU/L, n = 32 (Mokhtar
et al., 2017); 2.07 ± 0.83, n = 33 (Tang et al., 2017); and
1.2-4.2 IU/L in young adults (Nishizawa et al., 2013).
2.2 | Samples
Validation samples comprised matched fingerprick DBS
(fDBS), venous DBS (vDBS), and plasma samples
(‘Eugene200 Validation Set’) collected from a conve-
nience sample of 189 adults (≥18 years) from the Eugene/
Springfield, Oregon (USA) area between November 2014 and
February 2015 as described in detail previously (Eick, Kowal,
Barrett, Thiele, & Snodgrass, 2017). All samples were col-
lected in the evening between 5 PM and 9 PM, but exact time
of collection was not recorded and, therefore, not considered
in the analyses.
IRB approval for this study was obtained from the Com-
mittee for the Protection of Human Subjects, University of
Oregon (protocol # 7062016.007) and informed consent was
obtained from all participants.
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2.3 | Detection of TRACP-5b in DBS
As a first step to evaluate if TRACP-5b can be detected in
DBS, two different quality control (QC) DBS sets were cre-
ated. The first set of QC DBS was created by spiking 1 mL
of whole blood (WB) collected by venipuncture with
100 μL of 40 IU/L of TRACP-5b obtained by resuspending
the lyophilized standard provided with the kit in 500 μL
assay buffer and then pipetting out 60 μL of this mixture
onto Whatman 903 filter paper cards. Cards were then air
dried on the bench for 4 hours and then double bagged in
sealed plastic bags, each containing desiccant, and frozen at
−28C. The second set of quality controls was created by
collecting approximately 7 mL whole blood per tube by veni-
puncture in EDTA-coated Vacutainer tubes and centrifuging
the tubes in a Plasmafuge at 1500x g for 15 minutes. Plasma
and buffy coat were subsequently discarded, and then an
equal volume of saline (0.86 g NaCl/100 mL H2O) was
added and the tubes were gently mixed for 10 minutes. This
step was repeated an additional two times for a total of three
washes, and the saline supernatant was discarded following
the last centrifugation. An equal volume of washed red blood
cells obtained in this manner was spiked with sample diluent
from the kit containing 40 IU/L of TRACP-5b, and then
60 μL of this mixture was pipetted onto DBS cards to create
RBC QCs. Either one or two 6 mm punches from these QCs,
as well as WB and RBC zero controls (unspiked WB and
RBCs mixed with an equal volume of sample diluent with no
TRACP-5b added, respectively), were eluted in 180 μL of
sample diluent overnight at 4C.
TRACP-5b levels in these eluants were assessed using
the MyBiosource TRACP-5b ELISA kit with all steps per-
formed according to the manufacturer's protocol. Color was
allowed to develop for 20 minutes (manufacturer recom-
mends 15-30 minutes). Absorbance at 450 nm was read
using a spectrophotometer (BioTek ELx808) and a standard
curve was constructed using 4-parameter nonlinear regres-
sion as implemented in BioTek's Gen5 software.
2.4 | Measurement of TRACP-5b in E2V2 samples
TRACP-5b concentrations were assessed in 189 vDBS sam-
ples (stored at −80C; M:F 80:109) by eluting two 6-mm
punches in 180 μL sample eluent and loading 100 μL of this
per well. After plotting a histogram of the distribution of
TRACP-5b levels, 49 individuals with vDBS TRACP-5b
values spanning the range of measured TRACP-5b concen-
trations were identified, and TRACP-5b concentrations were
assessed in matched fDBS and undiluted plasma samples of
these 49 individuals, which were stored at −80C.
2.5 | Plasma/DBS comparisons
The relationships between plasma, fDBS, and vDBS TRACP-
5b concentrations in samples with a TRACP-5b level higher
than the LOD (1.1 IU/L) were assessed by Passing-Bablok
regression analysis as this method takes into account uncer-
tainty in both x- and y-values and is robust to outliers.
To assess the consistency of estimates based on plasma
vs DBS sample types and to assess if there was any bias, we
performed Bland-Altman analysis by plotting the difference
in plasma-equivalent fDBS values (transformed using the
appropriate Passing-Bablok regression equation) and plasma
values vs the average of these values, and evaluated the bias
and how many samples fell outside the 95% confidence
intervals (Bland & Altman, 1986).
2.6 | Parallelism
Four vDBS samples with a high endogenous concentration
of TRACP-5b were serially 2-fold diluted to obtain 1/2, 1/4,
and 1/8 dilutions. Only two of the four samples had a suffi-
ciently high original concentration to be able to obtain dilu-
tions that were within the assay range. For these samples,
the in-range measurements were multiplied to obtain the
equivalent “neat” concentration, and the CV of these con-
centrations was then calculated.
2.7 | Spike & recovery
Six 6-mm punches from six different individuals were
pooled and eluted in 600 μL of sample diluent. The ‘neat’
eluent, as well as ½ and 1/4 dilutions of this eluent were then
spiked with 8 IU/L, 4 IU/L, 2 IU/L, or 0 IU/L of TRACP-
5b standard provided with the kit and run in duplicate (total
of 24 wells). Mean recovery was calculated as the measured
TRACP-5b concentration in the spiked sample/expected
TRACP-5b concentration based on the TRACP-5b concen-
tration in the unspiked vDBS sample plus the known added
dose of the TRACP-5b standard.
2.8 | Precision: Intra- and interassay coefficients of
variation
Interassay coefficients of variation (CV) was calculated
by averaging the CVs of the concentrations of high and
low DBS controls across six plates. These DBS controls
were made by spiking 1 mL of whole blood with 40 IU/L
(high DBS control) or 0 IU/L TRACP-5b (low DBS con-
trol; only endogenous TRACP-5b being measured). Intra-
assay variability was calculated by running eight duplicate
wells each of the high and low DBS quality controls on
one plate and calculating the average of the high and low
DBS CVs.
2.9 | Limit of detection
The minimum detectable concentration (LOD) of TRACP-
5b in DBS was calculated by adding two standard devia-
tions to the mean optical density value of 14 wells con-
taining assay buffer only and calculating the corresponding
analyte concentration from the standard curve equation.
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2.10 | Analyte stability
Venous DBS cards from one individual with a moderate
TRACP-5b level (2.27 IU/L) were stored at 22C (controlled
ambient), 37C (hot ambient), and −28C (frozen) for 2, 7,
14, and 21 days after collection and then transferred to −80C.
Percentage recovery was calculated relative to the titer in the
sample stored at −80C immediately after collection and dried
and thawed only for the assay.
3 | RESULTS
3.1 | Detection of TRACP-5b in DBS
TRACP-5b levels were consistently higher in the spiked DBS
samples than the matched unspiked samples (Wilcoxon's
signed rank test, n = 12, W = 0, P < 0.05 one-tailed), indi-
cating that TRACP-5b can be measured from DBS. As
expected, use of two 6-mm punches yielded higher absor-
bance (and, therefore, concentration) values than use of a sin-
gle 6-mm punch, and the absorbance values obtained when
two punches were used were always greater than that of the
lowest standard (0.312 IU/L), whereas this was not always
the case for the single punches. Therefore, two 6-mm punches
were used in all subsequent assays.
3.2 | Measurement of TRACP-5b in E2V2 samples
The range of TRACP-5b levels measured in the vDBS after
removal of samples with values below the LOD (n = 6 sam-
ples had a TRACP level ≤ 1.1 IU/L; see below) was
1.12-5.58 IU/L, with a median value of 2.06 IU/L and a
mean of 2.28 IU/L. The range of TRACP-5b concentrations
in the 36 fDBS samples (after conversion to plasma equiva-
lents) ranged from 0.83 to 4.67 IU/L, with a mean concen-
tration of 2.29 IU/L and median concentration of 1.86 IU/L.
3.3 | Plasma/DBS comparisons
There was a clear linear relationship between levels of
TRACP-5b in pairwise comparisons of the various sample
types, as shown in the plots presented in Figure 1.
There was negligible bias in the fDBS vs plasma
Bland-Altman plot (bias = 0.06, 1 sample outside the 95%
CI; Figure 2A), indicating that TRACP-5b levels measured
in plasma and fDBS are not systematically different. There
was slightly more bias in the vDBS vs fDBS comparison
(bias = 0.35, three samples outside the 95% CI), with vDBS
values generally slightly higher than fDBS values (Figure 2B).
This bias is likely due to the generally smaller spot diameters
of the fDBS than the vDBS, with corresponding lower analyte
concentrations in punches taken from the fDBS than the vDBS
(George & Moat, 2016).
3.4 | Parallelism
The average CV of the two serially diluted samples was
30%, which is considered acceptable in commercial bio-
marker development laboratories (CV ≤30%) (Stevenson &
Purushothama, 2014).
3.5 | Spike and recovery
Percentage recovery ranged from 91% to 134%, with a mean
of 112.25%, indicating that the DBS matrix is a valid sample
matrix that does not contain factors that interfere with
TRACP-5b measurement using the MyBiosource ELISA kit
described here.
3.6 | Precision: Intra- and interassay CV
The intra-assay CV was 5.0%, and the interassay CV
was 12.1%.
3.7 | Limit of detection
The LOD of this assay as performed in our lab was 1.1 IU/L.
3.8 | Analyte stability
Average percentage recovery ranged from 93% to 116%
(mean, 101%) for samples stored at −28C for 2 to 28 days,
101% to 108% (mean, 104%) for samples stored at controlled
room temperature for 2 to 28 days, and 119% to 140%
(mean, 131%) for samples stored at 37C for 2 to 28 days.
No trend according to number of days stored was evident for
any of the storage temperatures.
4 | DISCUSSION
Using a rigorous approach of evaluation, modification, and
validation, we adapted an existing commercial ELISA that
specifically measures levels of TRACP-5b, a protein marker
of osteoclast activity and therefore bone resorption, for use
with DBS. Levels of TRACP-5b measured in fDBS were
consistent with those reported previously for serum/plasma
samples, with a mean plasma-converted TRACP-5b level of
2.29 ± 1.1 IU/L. In addition, TRACP-5b levels were higher
in males than females, as expected (mean plasma-equivalent
fDBS values: 2.59 ± 1.3 [SD] in males vs 2.07 ± 1.0 [SD] in
females). TRACP-5b levels in fDBS and vDBS were compa-
rable, indicating no significant differences in TRACP-5b dis-
tribution between capillary and venous blood. The dilution
response curve of the samples was parallel to that of the stan-
dard concentration response curve, albeit at the higher end of
the acceptable range. However, given that no samples in our
dataset had to be diluted relative to other samples (meaning
that all DBS samples that are run using this assay are likely to
be diluted identically), this is unlikely to be an issue. In addi-
tion, the good results of the spike and recovery experiment
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together with the initial spiking experimental results suggest
that the DBS matrix does not contain intrinsic factors that
interfere with accurate TRACP-5b measurement. Intra- and
interplate variability were within the acceptable range for
ELISA assays (≤10% and ≤15%-20%, respectively; https://
www.salimetrics.com/calculating-inter-and-intra-assay-
coefficients-of-variability). The interplate variability of 12.1%
was on the higher end of the acceptable range, although
what is considered acceptable is highly contingent on the
intended application of the assay (eg, clinical diagnoses vs
population-level research; see Semenova et al., 2012). Note that
for DBS-based ELISA assays, the interplate variability reflects
not only the inevitable variability between plates run on sepa-
rate days because of small variations in temperatures, instru-
mentation, pipetting, etc., but also the variability in analyte
measures taken from separate punches of a DBS (George &
Moat, 2016), which is not a source of variability when using
liquid samples (eg, serum, supernatant, urine) in ELISAs. The
higher limit-of-detection that we measured for this assay than
that reported for this assay by its manufacturer highlights the
importance of establishing lab-specific LODs when running
ELISA assays. Finally, recovery from samples stored at
−28C and controlled room temperature for periods ranging
from 1 to 28 days was acceptable, but the overinflated
recovery of TRACP-5b after storage at 37C suggests that
at this temperature, TRACP-5b in DBS breaks down into
degradation products that are immunoreactive with the cap-
ture antibody on the ELISA plates. We therefore recom-
mend storing DBS at −28C or lower after collection and
drying if TRACP-5b is to be measured. TRACP has been
observed to lose 20% activity per hour at room temperature
unless stabilized (Szulc & Bauer, 2013). Our finding that
TRACP-5b levels did not change drastically when stored at
room temperature suggests either that the filter paper
matrix protected against degradation, as has been demon-
strated for some analytes susceptible to degradation by
enzymes like hydrolases, esterases, and photocatalytic pro-
cesses (Freeman et al., 2018), or that the epitopes targeted by
the particular coating and detection antibodies used in our
ELISA assay were not affected by any potential degradation
that may have occurred.
Limitations of our study include using only the
MyBiosource TRACP-5b ELISA kit to measure TRACP-
5b levels in matched plasma samples rather than additional
TRACP-5b ELISA kits from different manufacturers with
presumably different antibodies targeting TRACP-5b to verify
our findings. In addition, we did not explicitly evaluate
the specificity of this assay for TRACP-5b vs TRACP-5a.
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FIGURE 1 Passing-Bablok curves showing the relationship between (A) fingerprick DBS (fDBS) and plasma levels of TRACP-5b, (B) venous DBS
(vDBS) and plasma levels of TRACP-5b, and (C) vDBS and fDBS levels of TRACP-5b as measured by ELISA. Passing-Bablok regression equations, the
number of samples analyzed, and the male:female (M:F) ratio are indicated in the right hand corners of the graphs
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FIGURE 2 Bland-Altman plots of the difference in (A) plasma and plasma-equivalent fingerprick DBS (fDBS) TRACP-5b values vs the average of these
values (n = 49) and (B) fDBS and venous DBS (vDBS) TRACP-5b values vs the average of these values (n = 49). Bias was negligible for both plasma vs
fDBS (0.06) and fDBS vs vDBS comparisons (0.35), with only one and three points outside the 95% confidence intervals indicated by the dotted lines,
respectively. These results indicate no significant bias in TRACP-5b measured in plasma vs TRACP-5b measured in fDBS or TRACP-5b measured in fDBS
vs TRACP-5b measured in vDBS
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The manufacturer, however, assured lack of cross-reactivity
against TRACP-5a based on proprietary data.
Overall, we have demonstrated the feasibility of mea-
suring TRACP-5b from DBS samples, adding to the arse-
nal of minimally invasive techniques available to human
biologists. Measurement of TRACP5b levels in DBS will
open the door to investigating population differences in
bone turnover and the effects of factors such as senescence,
nutrition, disease, exercise, pregnancy, and lactation on
bone mass among nonindustrialized populations at low risk
for osteoporosis, which can provide important insights into
the dynamics of bone formation and bone loss. In addition,
this biomarker can be used to gain insight into the relation-
ship between parity and bone density by applying it to
natural fertility, subsistence populations for which bone
density and high resolution environmental/lifestyle data are
available.
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